Biomarker Type: Genomic
-
Performance verification of a plasma-based PD-L1 test that reliably measures mRNA expression from patients with NCSLC
-
Concordance between IHC and a new Blood-based Expression Assay for the Detection of PD-L1 in Patients Diagnosed with NSCLC
-
Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma.
-
Utility of a targeted NSCLC genomic test for cfDNA variants in the community setting
-
Early feasibility and development of multiplexed, single-reaction assay for ALK, ROS1 and RET novel ddPCR fusions
-
Development of ddPCR blood-based diagnostic tests that simultaneously measure mRNA expression from immune and cancer cells.
-
Utility of blood-based genomic and proteomic tests for non-small cell lung cancer
-
Blood-based Profiling of NSCLC with CLIA certified cell-free DNA Tests for EGFR, KRAS and BRAF Point Mutations and Utility in Clinical Practice
-
Profiling Blood from NSCLC Patients for Clinically Actionable Gene Variants using GeneStrat
-
Development of a Rapid Blood-based Test for EGFR Sensitizing and Resistance Mutations in NSCLC